Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms

PURPOSE: Netarsudil is a Rho kinase/norepinephrine transporter inhibitor currently in phase 3 clinical development for glaucoma treatment. We investigated the effects of its active metabolite, netarsudil-M1, on outflow facility (C), outflow hydrodynamics, and morphology of the conventional outflow p...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Invest Ophthalmol Vis Sci
Prif Awduron: Ren, Ruiyi, Li, Guorong, Le, Thuy Duong, Kopczynski, Casey, Stamer, W. Daniel, Gong, Haiyan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: The Association for Research in Vision and Ophthalmology 2016
Pynciau:
Glaucoma
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5114035/
https://ncbi.nlm.nih.gov/pubmed/27842161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1167/iovs.16-20189
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg